---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-011627"
form_type: "8-K"
ticker: "CVM"
cik: "0000725363"
company_name: "CEL SCI CORP"
filed_at: "2022-08-22T23:59:59+00:00"
generated_at: "2026-06-23T22:23:18.614637+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CEL-SCI Phase 3 Multikine shows 14.1% 5-year OS benefit in lower-risk head and neck cancer

## Summary
- 8.1% ORR for Multikine+CIZ vs 0% SOC in ITT; 15.2% ORR in proposed indication (n=158).
- 14.1% absolute OS advantage at 5 years in lower-risk arm (62.7% vs 48.6%; HR=0.68).
- Median OS nearly 4 years longer: 101.7 months vs 55.2 months for SOC in proposed indication.
- No excess safety issues; adverse event rates similar across all treatment arms.
- Company plans to submit BLA to FDA for indication covering ~210,000 patients globally.

## SEC filing metadata
- accession: 0001654954-22-011627
- form_type: 8-K
- ticker: CVM
- cik: 0000725363
- company_name: CEL SCI CORP
- filed_at: 2022-08-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/725363/000165495422011627/0001654954-22-011627-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/725363/000165495422011627/cvm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-011627
- JSON: https://secwatch.observer/filing/0001654954-22-011627.json
- Plain text: https://secwatch.observer/filing/0001654954-22-011627.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.